Cannabinoid-based medicines (CBMs) have garnered attention due to their anti-inflammatory potential in people with HIV (PWH), whose comorbidities are driven by chronic inflammation. The expanded endocannabinoid system (or endocannabinoidome, eCBome) is an important target of cannabinoids that cross talks with gut microbiota and regulates many homeostatic processes and inflammation. In a prospective, pilot clinical trial, PWH on antiretroviral therapy (ART) were randomly assigned to receive cannabidiol (CBD) ± Δ9-tetrahydrocannabinol (THC) capsules for 12 weeks, titrating doses as tolerated, to examine the impact of cannabinoids on plasma eCBome mediators and gut microbiota.
Methods:
Ten individuals were randomized, five to the CBD+THC arm and five to the CBD-only arm. Eight individuals completed the study. Plasma was collected at each visit and measured in batches by liquid chromatography (LC)-mass spectrophotometry (MS). The eCBome mediators were measured at each visit by LC-MS-MS, whereby fecal microbiota composition was assessed by 16S rDNA sequencing at the initiation and end of treatment.
Results:
Plasma concentrations of THC and CBD metabolites varied throughout the course of the study. Capsule administration resulted in a significant decrease in monoacylglycerols 2-eicosapentaenoylglycerol (2-EPG) and 2-oleoylglycerol (2-OG) after treatment. No changes were observed in the levels of other mediators measured. PWH in the distinct treatment arms had different fecal bacterial taxa at baseline. These differences persisted through the course of the study and were not altered by cannabinoid administration. However, Coprobacillus and Lachnospiraceae UCG001 relative abundance was lower, while Collinsella was higher, in the THC/CBD compared with the CBD arm.
Conclusion:
2-EPG and 2-OG were both reduced following cannabinoid administration. No changes in fecal bacterial taxa were observed following 12 weeks of treatment. Larger studies are needed to understand if these changes reflect adaptation of the eCBome to the beneficial effects of CBM in PWH.
CostiniukCT, AngelJB. Human immunodeficiency virus and the gastrointestinal immune system: Does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol, 2012; 5(6):596–604.
2.
KimCJ, WalmsleySL, RaboudJM, et al.Can probiotics reduce inflammation and enhance gut immune health in people living with HIV: Study designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) pilot trials. HIV Clin Trials, 2016; 17(4):147–157.
3.
SinghS, GironLB, ShaikhMW, et al.Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging. Microbiome, 2024; 12(1):31.
4.
BabanB, KhodadadiH, SallesEL, et al.Inflammaging and cannabinoids. Ageing Res Rev, 2021; 72:101487.
5.
CostiniukCT, JenabianMA. Cannabinoids and inflammation: Implications for people living with HIV. AIDS, 2019; 33(15):2273–2288.
6.
CostiniukCT, SaneeiZ, RoutyJP, et al.Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. BMJ Open, 2019; 9(1):e024793.
7.
HsuDC, SeretiI. Serious non-AIDS events: Therapeutic targets of immune activation and chronic inflammation in HIV infection. Drugs, 2016; 76(5):533–549.
8.
CostiniukCT, SaneeiZ, SalahuddinS, et al.Cannabis consumption in people living with HIV: Reasons for use, secondary effects, and opportunities for health education. Cannabis Cannabinoid Res, 2019; 4(3):204–213.
9.
Di MarzoV, PiscitelliF. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics, 2015; 12(4):692–698.
10.
SimardM, ArchambaultAS, LavoieJC, et al.Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol and N-acyl-ethanolamine families. Biochem Pharmacol, 2022; 205:115261.
11.
MockED, GagesteinB, van der SteltM. Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. Prog Lipid Res, 2023; 89:101194.
12.
TurcotteC, ChouinardF, LefebvreJS, et al.Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol, 2015; 97(6):1049–1070.
13.
ParkT, ChenH, KevalaK, et al.N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. J Neuroinflammation, 2016; 13(1):284.
14.
RinneP, Guillamat-PratsR, RamiM, et al.Palmitoylethanolamide promotes a proresolving macrophage phenotype and attenuates atherosclerotic plaque formation. Arterioscler Thromb Vasc Biol, 2018; 38(11):2562–2575.
15.
TyrtyshnaiaA, BondarA, KonovalovaS, et al.N-Docosahexanoylethanolamine reduces microglial activation and improves hippocampal plasticity in a murine model of neuroinflammation. Int J Mol Sci, 2020; 21(24).
16.
TyrtyshnaiaA, KonovalovaS, BondarA, et al.Anti-inflammatory activity of N-docosahexaenoylethanolamine and N-eicosapentaenoylethanolamine in a mouse model of lipopolysaccharide-induced neuroinflammation. Int J Mol Sci, 2021; 22(19).
17.
TyrtyshnaiaA, KonovalovaS, PonomarenkoA, et al.Fatty acid-derived N-acylethanolamines dietary supplementation attenuates neuroinflammation and cognitive impairment in LPS murine model. Nutrients, 2022; 14(18).
18.
TyrtyshnaiaAA, EgorovaEL, StarinetsAA, et al.N-Docosahexaenoylethanolamine attenuates neuroinflammation and improves hippocampal neurogenesis in rats with sciatic nerve chronic constriction injury. Mar Drugs, 2020; 18(10).
19.
CrowleyK, KiragaL, MiszczukE, et al.Effects of cannabinoids on intestinal motility, barrier permeability, and therapeutic potential in gastrointestinal diseases. Int J Mol Sci, 2024; 25(12).
20.
CuddiheyH, MacNaughtonWK, SharkeyKA. Role of the endocannabinoid system in the regulation of intestinal homeostasis. Cell Mol Gastroenterol Hepatol, 2022; 14(4):947–963.
21.
MontecuccoF, Di MarzoV. At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci, 2012; 33(6):331–340.
22.
TurcotteC, BlanchetMR, LavioletteM, et al.The CB(2) receptor and its role as a regulator of inflammation. Cell Mol Life Sci, 2016; 73(23):4449–4470.
23.
XieY, SunJ, WeiL, et al.Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals. BMC Microbiol, 2021; 21(1):11.
24.
IannottiFA, Di MarzoV. The gut microbiome, endocannabinoids and metabolic disorders. J Endocrinol, 2021; 248(2):R83–R97.
25.
CaniPD, PlovierH, Van HulM, et al.Endocannabinoids–at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol, 2016; 12(3):133–143.
26.
Mboumba BouassaRS, GiorginiG, SilvestriC, et al.Plasma endocannabinoidome and fecal microbiota interplay in people with HIV and subclinical coronary artery disease: Results from the Canadian HIV and Aging Cohort Study. iScience, 2024; 27(8):110456.
27.
MurrayCH, JavanbakhtM, ChoGD, et al.Changes in immune-related biomarkers and endocannabinoids as a function of frequency of cannabis use in people living with and without HIV. Cannabis Cannabinoid Res, 2024; 9(3):e897–e906.
28.
Mboumba BouassaRS, ComeauE, AlexandrovaY, et al.Effects of oral cannabinoids on systemic inflammation and viral reservoir markers in people with HIV on antiretroviral therapy: Results of the CTN PT028 pilot clinical trial. Cells, 2023; 12(14).
29.
CallahanBJ, McMurdiePJ, RosenMJ, et al.DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods, 2016; 13(7):581–583.
30.
Callahan MRMaBJ. Silva 138.1 prokaryotic SSU taxonomic training data formatted for DADA2. Zenodo, 2021.
31.
LuY, ZhouG, EwaldJ, et al.MicrobiomeAnalyst 2.0: Comprehensive statistical, functional and integrative analysis of microbiome data. Nucleic Acids Res, 2023; 51(W1):W310–W8.
32.
Mboumba BouassaRS, NeedhamJ, NohynekD, et al.Safety and tolerability of oral cannabinoids in people living with HIV on long-term ART: A randomized, open-label, interventional pilot clinical trial (CTNPT 028). Biomedicines, 2022; 10(12).
33.
MerrickJ, LaneB, SebreeT, et al.Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis Cannabinoid Res, 2016; 1(1):102–112.
34.
HartED, MullenL, VikingssonS, et al.Conversion of water-soluble CBD to Δ9-THC in synthetic gastric fluid–An unlikely cause of positive drug tests. J Anal Toxicol, 2023; 47(7):632–635.
35.
FosterZS, SharptonTJ, GrunwaldNJ. Metacoder: An R package for visualization and manipulation of community taxonomic diversity data. PLoS Comput Biol, 2017; 13(2):e1005404.
36.
MillarSA, StoneNL, BellmanZD, et al.A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol, 2019; 85(9):1888–1900.
37.
LucasCJ, GalettisP, SchneiderJ. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol, 2018; 84(11):2477–2482.
38.
DevinskyO, CilioMR, CrossH, et al.Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014; 55(6):791–802.
39.
BabayevaM, LoewyZG. Cannabis pharmacogenomics: A path to personalized medicine. Curr Issues Mol Biol, 2023; 45(4):3479–3514.
40.
QuercioliA, PatakyZ, VincentiG, et al.Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J, 2011; 32(11):1369–1378.
41.
JehleJ, GoerichH, BindilaL, et al.Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. PLoS One, 2019; 14(12):e0227142.
42.
QuercioliA, MontecuccoF, PatakyZ, et al.Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: Relation to alterations in endocannabinoids and adipocytokines. Eur Heart J, 2013; 34(27):2063–2073.
43.
QuercioliA, CarboneF, BonaventuraA, et al.Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. Int J Cardiol, 2017; 231:1–5.
44.
Sanchez-TapiaM, Tobon-CornejoS, NoriegaLG, et al.Hepatic steatosis can be partly generated by the gut microbiota-mitochondria axis via 2-oleoyl glycerol and reversed by a combination of soy protein, chia oil, curcumin and nopal. Nutrients, 2024; 16(16).
45.
YangM, QiX, LiN, et al.Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun, 2023; 14(1):228.
46.
van WelzenBJ, MudrikovaT, El IdrissiA, et al.A review of non-alcoholic fatty liver disease in HIV-infected patients: The next big thing? Infect Dis Ther, 2019; 8(1):33–50.
47.
CalderPC. Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol, 2013; 75(3):645–662.
48.
BalversMG, VerhoeckxKC, PlastinaP, et al.Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties. Biochim Biophys Acta, 2010; 1801(10):1107–1114.
49.
RochefortG, ProvencherV, Castonguay-ParadisS, et al.Intuitive eating is associated with elevated levels of circulating omega-3-polyunsaturated fatty acid-derived endocannabinoidome mediators. Appetite, 2021; 156:104973.
50.
GrinspoonSK, FitchKV, OvertonET, et al.Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J, 2019; 212:23–35.
51.
LozuponeCA, StombaughJI, GordonJI, et al.Diversity, stability and resilience of the human gut microbiota. Nature, 2012; 489(7415):220–230.
52.
VinoloMA, RodriguesHG, NachbarRT, et al.Regulation of inflammation by short chain fatty acids. Nutrients, 2011; 3(10):858–876.
53.
RancanL, Linillos-PradilloB, CentenoJ, et al.Protective actions of cannabidiol on aging-related inflammation, oxidative stress and apoptosis alterations in liver and lung of Long-Evans rats. Antioxidants (Basel), 2023; 12(10).
54.
LiuY. Alzheimer’s disease, aging, and cannabidiol treatment: A promising path to promote brain health and delay aging. Mol Biol Rep, 2024; 51(1):121.
55.
NiB, LiuY, DaiM, et al.The role of cannabidiol in aging. Biomed Pharmacother, 2023; 165:115074.
56.
GoeppM, MilburnJV, ZhangB, et al.Age-related impairment of intestinal inflammation resolution through an eicosanoid-immune-microbiota axis. Cell Host Microbe, 2025; 33(5):671–687 e6.
57.
BabakhaniK, KucinskasAL, YeX, et al.Aging immunity: Unraveling the complex nexus of diet, gut microbiome, and immune function. Immunometabolism (Cobham), 2025; 7(2):e00061.
58.
RudermanSA, HuntPW, Beck-EngeserG, et al.Biomarkers of microbial translocation and generalized inflammation are associated with frailty among people with HIV. AIDS, 2025; 39(2):153–161.
59.
AndreR, GomesAP, Pereira-LeiteC, et al.The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals (Basel), 2024; 17(11).
60.
Mboumba BouassaRS, NeedhamJ, NohynekD, et al.Feasibility of a randomized, interventional pilot clinical study of oral cannabinoids in people with HIV on antiretroviral therapy: CTNPT 028. J Pers Med, 2024; 14(7).
61.
RocafortM, GootenbergDB, LuevanoJMJr, et al.HIV-associated gut microbial alterations are dependent on host and geographic context. Nat Commun, 2024; 15(1):1055.
62.
HamasakiH. Exercise and gut microbiota: Clinical implications for the feasibility of Tai Chi. J Integr Med, 2017; 15(4):270–281.
63.
RizzettoL, FavaF, TuohyKM, et al.Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex. J Autoimmun, 2018; 92:12–34.
64.
Bourdeau-JulienI, Castonguay-ParadisS, RochefortG, et al.The diet rapidly and differentially affects the gut microbiota and host lipid mediators in a healthy population. Microbiome, 2023; 11(1):26.
65.
ConlonMA, BirdAR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients, 2014; 7(1):17–44.
66.
LarsenJM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology, 2017; 151(4):363–374.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
